Skip to Content

Join the 'Carcinoid Syndrome' group to help and get support from people like you.

Carcinoid Syndrome News

FDA Approves New Indication for Ipsen’s Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

Posted 21 Sep 2017 by Drugs.com

Paris (France) September 18, 2017 – Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental indication for Somatuline Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analogue rescue therapy. Somatuline Depot is also approved for the improvement of progression-free survival (PFS) in patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).[1] Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen, said: “The new indication for Somatuline® Depot offers patients in the U.S. a valuable treatment option for debilitating carcinoid syndrome associated with neuroendocrine tumors. It also reaffirms I ... Read more

Related support groups: Lanreotide, Carcinoid Syndrome, Somatuline Depot

FDA Approves Xermelo (telotristat ethyl) as First and Only Oral Treatment for Carcinoid Syndrome Diarrhea in Cancer Patients with Metastatic Neuroendocrine Tumors

Posted 2 Mar 2017 by Drugs.com

The Woodlands, Texas, February 28, 2017 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Xermelo (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy . Carcinoid syndrome is a rare and debilitating condition that affects people with metastatic neuroendocrine tumors (mNETs). Xermelo targets the overproduction of serotonin inside mNET cells , providing a new treatment option for patients suffering from carcinoid syndrome diarrhea. This new treatment is now available by prescription and will be in select specialty pharmacies beginning March 6, 2017. “Today’s approval of Xermelo represents a shift in the treatment paradigm of carcinoid syndr ... Read more

Related support groups: Carcinoid Tumor, Carcinoid Syndrome, Carcinoid Syndrome Diarrhea, Telotristat, Xermelo

Xermelo Approved for Tumor-Related Diarrhea

Posted 1 Mar 2017 by Drugs.com

WEDNESDAY, March 1, 2017 – Xermelo (telotristat ethyl) tablets have been approved by the U.S. Food and Drug Administration to treat adults with carcinoid syndrome diarrhea, one of a collection of symptoms related to rare carcinoid tumors. Most of these slow-growing tumors are found in the gastrointestinal tract, the agency said in a news release. Carcinoid syndrome occurs in fewer than 10 percent of people with carcinoid tumors, commonly after the tumor has spread to the liver. The tumor releases an excess amount of the hormone serotonin, leading to diarrhea. Complications can include weight loss, malnutrition, dehydration and an imbalance of electrolytes. Xermelo, taken three times daily with food, is designed to inhibit production of serotonin by carcinoid tumors, the FDA said. The drug was evaluated in clinical studies involving 90 adults with carcinoid syndrome diarrhea, comparing ... Read more

Related support groups: Cancer, Carcinoid Syndrome, Carcinoid Syndrome Diarrhea, Telotristat, Xermelo

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Prostate Cancer, Tamoxifen, Fluorouracil, Tretinoin, Arimidex, Lupron Depot, Femara, Lung Cancer, Renal Cell Carcinoma, Gleevec, Rituxan, Isotretinoin

Ask a Question

Further Information

Related Condition Support Groups

Carcinoid Syndrome Diarrhea, Carcinoid Tumor

Related Drug Support Groups

lanreotide, Somatuline Depot